- Home
- FFA vs AVIR Comparison
FFA vs AVIR Comparison
Compare FFA & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FFA | AVIR |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 428.9M | 434.5M |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FFA | AVIR |
|---|---|---|
| Price | $21.87 | $4.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 28.0K | ★ 259.4K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.50 | $2.78 |
| 52 Week High | $23.24 | $6.45 |
Technical Indicators
Market Signals| Indicator | FFA | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 50.15 |
| Support Level | $21.67 | $4.14 |
| Resistance Level | $22.04 | $4.59 |
| Average True Range (ATR) | 0.30 | 0.18 |
| MACD | -0.10 | 0.05 |
| Stochastic Oscillator | 18.12 | 83.33 |
Price Performance
Historical ComparisonAbout FFA First Trust Enhanced Equity Income Fund
First Trust Enhanced Equity Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide high level of current income and gains and, to a lesser extent, capital appreciation. The Fund pursues its investment objective by investing in a diversified portfolio of equity securities.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.